Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 27 Oct 2021
TGA approval for Pfizer COVID-19 vaccine booster dose
27 October 2021 - The TGA has approved a booster dose of the Pfizer COVID-19 vaccine for individuals 18 years ...
Posted by Michael Wonder on 27 Oct 2021
Democratic senators raise concerns with potential FDA pick
26 October 2021 - Sens. Joe Manchin and Richard Blumenthal have concerns with President Biden’s rumoured nominee for the FDA, ...
Posted by Michael Wonder on 27 Oct 2021
TGA approves booster doses of the Pfizer COVID-19 vaccine Comirnaty
27 October 2021 - The TGA has provisionally approved a booster dose of the Pfizer COVID-19 vaccine, Comirnaty, for individuals ...
Posted by Michael Wonder on 26 Oct 2021
Evrysdi is not included in the high-cost protection
22 October 2021 - TLV assesses that the costs of using Evrysdi are too high in relation to the benefit the ...
Posted by Michael Wonder on 26 Oct 2021
The evolution of the Italian National Health Service
22 October 2021 - 40 years ago, Italy saw the birth of a national, universal health care system (Servizio Sanitario Nazionale ...
Posted by Michael Wonder on 26 Oct 2021
Strengthening the reporting of observational studies in epidemiology using Mendelian randomisation: the STROBE-MR Statement
26 October 2021 - An international expert committee, informed by the methodological framework for guideline development of the Enhancing the Quality ...
Posted by Michael Wonder on 26 Oct 2021
Large employer group launches pharmacy benefit management business
26 October 2021 - A non-profit coalition of nearly 40 companies, including U.S. retailers Walmart and Costco, said on Monday it ...
Posted by Michael Wonder on 26 Oct 2021
Cystic fibrosis medicine added to PHARMAC's options for investment list
27 October 2021 - PHARMAC has announced that Vertex’s triple combination modulator therapy, known in some countries as Trikafta, has ...
Posted by Michael Wonder on 26 Oct 2021
Lilly pipeline success strengthens future growth potential
27 October 2021 - Lilly announces today its U.S. submission of tirzepatide in type 2 diabetes using a priority review ...
Posted by Michael Wonder on 26 Oct 2021
MHRA licenses Ryeqo for symptoms of uterine fibroids
26 October 2021 - The Medicines and Healthcare products Regulatory Agency has licensed Gedeon Richter UK’s Ryeqo (relugolix combination therapy) ...
Posted by Michael Wonder on 26 Oct 2021
Geron enters new innovative licensing and access pathway in the United Kingdom for imetelstat
25 October 2021 - Innovation Passport Designation Awarded to Imetelstat for the Treatment of Lower Risk Myelodysplastic Syndromes. ...
Posted by Michael Wonder on 26 Oct 2021
Theratechnologies announces reimbursement agreement in Italy for Trogarzo for eligible patients with multi-drug resistant HIV-1
26 October 2021 - Theratechnologies is pleased to announce that it has reached an agreement with the Italian Medicines Agency, AIFA, ...
Posted by Michael Wonder on 26 Oct 2021
Eyenovia announces reclassification of MydCombi as drug device combination product by FDA
25 October 2021 - Company received complete response letter with additional requests and is preparing necessary documents for expedited resubmission, ...
Posted by Michael Wonder on 26 Oct 2021
Bausch + Lomb and Clearside Biomedical announce FDA approval of Xipere (triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment of macular oedema Associated with Uveitis
25 October 2021 - Xipere is the first and only medicine to be approved in the United States for delivery ...
Posted by Michael Wonder on 26 Oct 2021
NICE draft guidance does not recommend tucatinib for advanced breast cancer
26 October 2021 - NICE has today published draft guidance for public consultation which does not recommend tucatinib (Tukysa; Seagen), in ...